Showing 61 - 80 results of 114,460 for search '(( a non decrease ) OR ( 5 ((step decrease) OR (((teer decrease) OR (a decrease)))) ))', query time: 1.63s Refine Results
  1. 61

    The novel <i>carboxylesterase 1</i> variant c.662A>G may decrease the bioactivation of oseltamivir in humans by Jaeseong Oh (3947381)

    Published 2017
    “…A novel <i>CES1</i> c.662A>G single nucleotide polymorphism (SNP) was predicted to decrease CES1 enzymatic activity in an <i>in silico</i> analysis. …”
  2. 62

    Aged blood factors decrease cellular responses associated with delayed gingival wound repair by María Paz Saldías (4430032)

    Published 2017
    “…<div><p>Aging is a gradual biological process characterized by a decrease in cell and organism functions. …”
  3. 63
  4. 64
  5. 65
  6. 66
  7. 67

    Impaired Functions of Macrophage from Cystic Fibrosis Patients: CD11b, TLR-5 Decrease and sCD14, Inflammatory Cytokines Increase by Karin Simonin-Le Jeune (464354)

    Published 2013
    “…Furthermore expression of CD11b and TLR-5 were sorely decreased on CF macrophages. Beside, no difference was observed for mCD14, CD16, CD64, TLR-4 and TLR1/TLR-2 expressions. …”
  8. 68
  9. 69
  10. 70

    Influenza virus infection decreases CLEC7A (Dectin1) mRNA and reduces phagocytosis of zymosan by AM. by Jieru Wang (179734)

    Published 2012
    “…<p>Panel A. Human AM were cultured and infected by PR/8 at a MOI of 0.5. …”
  11. 71
  12. 72
  13. 73

    Different response of visASCs to a micro-local oxygen concentration decrease in metabolically active sites of the adipose tissue. by Wilfredo Oliva-Olivera (301968)

    Published 2017
    “…However, hypox-visASCs from MS patients show a lower ability to actively participate in or stimulate the formation of microvascular structures, while they favor the accumulation of CD11C<sup>+</sup> and CD163<sup>+</sup> macrophages in the adipose tissue through their contribution to the increased tissue levels of MCP1. ↑ Increased response; <b>↓</b> Decreased response; → Hypox-visASCs main response NonMS: obese subjects without metabolic syndrome; MS: obese subjects with metabolic syndrome; visASC: visceral adipose tissue-derived multipotent mesenchymal cells; hypox-visASCs: visASC under hypoxia; NOX5: NADPH Oxidase 5; SDF1α: stromal cell-derived factor 1α; VEGF: vascular endothelial growth factor; MCP1: monocyte chemoattractant protein 1; CD11C<sup>+</sup>, CD163<sup>+</sup>: proinflammatory macrophage cell-surface markers.…”
  14. 74

    <i>Ext1</i> mutant lungs exhibit a decrease in SHH-FGF10 signaling. by Hua He (120374)

    Published 2017
    “…<p>(A) qPCR analysis of key components of FGF signaling pathway in lungs from E14.5. …”
  15. 75

    Changes in V<sub>T</sub> and FRC during decreasing PEEP. by Marcus J. Kitchen (444759)

    Published 2014
    “…<p>The increase in tidal volume (V<sub>T</sub>) and decrease in functional residual capacity (FRC) when positive end-expiratory pressure (PEEP) is decreased in 5 cmH<sub>2</sub>O stepwise decrements (10-5-0PEEP), large steps (10-0PEEP) and from a small step (5-0PEEP) in the ventilated lung. …”
  16. 76

    Image_5_miR-144-5p and miR-451a Inhibit the Growth of Cholangiocarcinoma Cells Through Decreasing the Expression of ST8SIA4.tif by Wan Fu (3681799)

    Published 2021
    “…This study aimed to investigate the action mechanism of miR-144-5p and miR-451a in cholangiocarcinoma. We found that miR-144-5p and miR-451a were significantly decreased in cholangiocarcinoma patient samples compared to the adjacent normal bile duct samples. …”
  17. 77
  18. 78
  19. 79

    Vectorized siRNA TMPRSS2-ERG IV-SQ impaired tumour growth and restored differentiation <i>in vivo</i>. by Giorgia Urbinati (554921)

    Published 2015
    “…<p><b>a.</b> SCID mice (n = 5/group) bearing VCaP tumour xenografts were injected intravenously either with NaCl 0.9%, non-vectorized siRNA TMPRSS2-ERG IV, NPs siRNA control-SQ or NPs siRNA TMPRSS2-ERG IV-SQ twice per week during 6 weeks (1.8 mg/kg/mouse cumulative dose). …”
  20. 80

    Table_1_v2_A long waiting time from diagnosis to treatment decreases the survival of non-small cell lung cancer patients with stage IA1: A retrospective study.docx by Bin Liu (5899)

    Published 2022
    “…After adjusting for other confounders, the waiting time was identified as an independent prognostic factor.</p>Conclusions<p>A long waiting time before treatment may decrease the survival of stage IA1 NSCLC patients. …”